OBJECTIVE To evaluate the feasibility and impact of telelactation via personal electronic devices on breastfeeding duration and exclusivity among rural women. METHODS The Tele-MILC trial, a pragmatic, parallel design trial,… Click to show full abstract
OBJECTIVE To evaluate the feasibility and impact of telelactation via personal electronic devices on breastfeeding duration and exclusivity among rural women. METHODS The Tele-MILC trial, a pragmatic, parallel design trial, recruited 203 women during their postpartum hospitalization in a critical access hospital in Pennsylvania and randomized them to receive telelactation (n=102) or usual care (n=101). We used intent-to-treat (ITT) and instrumental variable (IV) approaches to analyze study data for the 187 participants who completed follow-up. The primary outcomes were any breastfeeding and exclusive breastfeeding at 12 weeks postpartum. RESULTS Among participants in the telelactation arm, 50% (47/94) reported participating in video calls. At 12 weeks, 71% of participants in the telelactation arm vs. 68% of control participants were breastfeeding in the ITT model (3% difference, p=0.73), whereas 73% of participants in the telelactation arm vs. 68% of control participants were breastfeeding in the IV model (5% difference, p=0.74). Among participants who were still breastfeeding at 12 weeks, 51% participants in the telelactation arm were breastfeeding exclusively vs. 46% of control participants in the ITT model (5% difference, p=0.47), whereas 56% of participants in the telelactation arm were breastfeeding exclusively vs. 45% of control participants in the IV model (11% difference, p=0.48). In all models, participants in the telelactation arm were breastfeeding at higher rates; however, differences were not statistically significant. CONCLUSIONS This trial demonstrated that telelactation can be implemented with a rural underserved population. Though this trial was not powered to detect differences in breastfeeding duration and exclusivity, and none were observed, telelactation remains a promising approach for further investigation. ClinicalTrials.gov Identifier: NCT02870413.
               
Click one of the above tabs to view related content.